A "blockbuster drug" is a term used in the pharmaceutical industry to describe a medication that is extremely successful in the market, generating significant sales and revenue.

Intellia Therapeutics has revealed the initiation of their Phase 3 clinical trial named MAGNITUDE, where the first participant received a one-time CRISPR therapy, NTLA-2001, aimed at treating cardiac amyloidosis caused by transthyretin.

Glutathione, a diminutive molecule drug, is a versatile medication used to treat a diverse range of medical conditions.

During the 2024 ACS Spring Meeting, Brenig Therapeutics showcased novel findings related to their leading LRRK2 inhibitor, which is aimed at tackling Parkinson's disease.

In this article, we will focus on Sosei Heptares, a leading company in the field of GPCR new drug development, and its GPCR research and development pipeline.

On March 14, 2024, Eli Lilly unveiled a WO patent for a crystalline salt form of an FGFR3 inhibitor, likely relating to LOXO-435's structure, within the pyrimido[4,5-b]pyrazine compound class.

Ezetimibe, an enigmatic small molecule drug, bewilders the medical community with its ability to inhibit the NPC1L1 protein.

Citius Pharmaceuticals Reveals the U.S. FDA's Approval of a Revised BLA for LYMPHIR™ (Denileukin Diftitox), Aimed at Treating Reoccuring or Treatment-Resistant Cutaneous T-Cell Lymphoma in Adults.

This piece will highlight GPCR targets and notable pipelines from Chugai, UCB, Ascendis, and BridgeBio at the 2024 JP Morgan Healthcare Conference.

Shanghai Henlius Biotech, Inc. has reported the commencement of a phase 1 clinical study for HLX42, by administering the initial dose to a participant.

Chlorthalidone, a small molecule drug, operates via the inhibition of the NCC protein that is responsible for sodium and chloride reabsorption in the kidneys.

Formycon and Fresenius Kabi have concluded a resolution for their biosimilar contender FYB202, based on ustekinumab, targeting markets in Europe and Canada.